Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trialC Bourgier, S Kerns, S Gourgou, et al.
British Journal of Cancer|February 21, 2013
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerD W Miles, S L de Haas, L Y Dirix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III studyW Jacot, N Firmin, L Roca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)M Gershanovich, H A Chaudri, D Campos, et al.
Voprosy Onkologii|October 26, 1999
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]M Gershanovich, Kh Chaudri, D Campos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerV Diéras, M Campone, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trialJ-Y Pierga, F-C Bidard, C Cropet, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2001
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancerM Namer, P Soler-Michel, F Turpin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 13, 2002
["Standards, Options and Recommendations 2001" for radiotherapy in patients with non-metastatic infiltrating breast cancer. Update. National Federation of Cancer Campaign Centers (FNCLCC)]A Fourquet, B Cutuli, E Luporsi, et al.
Pageof 3